IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

Clinical Immunology

Volumn 132, Issue 1, 2009, Pages 71-82

  Simpson Abelson, Michelle R ^a   Purohit, Vivek S ^a   Pang, Wing Man ^a   Iyer, Vandana ^a   Odunsi, Kunle ^b   Demmy, Todd L ^b   Yokota, Sandra J ^a   Loyall, Jenni L ^a   Kelleher Jr , Raymond J ^a   Balu Iyer, Sathy ^a   Bankert, Richard B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Interleukin 12; Liposomes; SCID mice; T cells; Tumor immunotherapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; LIPOSOME; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; ENCAPSULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IN SITU HYBRIDIZATION; IN VIVO CULTURE; LEUKOCYTE; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MICROENVIRONMENT; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; SINGLE DRUG DOSE; STROMA CELL; SUSTAINED DRUG RELEASE; T LYMPHOCYTE; THERAPY EFFECT; TUMOR CELL; TUMOR IMMUNITY; TUMOR XENOGRAFT;

ANIMALS; CIRCULAR DICHROISM; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; INTERLEUKIN-12; KI-67 ANTIGEN; LIPOSOMES; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SPECTROMETRY, FLUORESCENCE; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349218153     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.03.516     Document Type: Article

References (50)

1. Agrawal S., Marquet J., Delfau-Larue M.H., et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J. Clin. Invest. 102 (1998) 1715-1723
2. Radoja S., Saio M., and Frey A.B. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J. Immunol. 166 (2001) 6074-6083
3. Broderick L., and Bankert R.B. Memory T Cells in Human Tumor and Chronic Inflammatory Microenvironments: Sleeping Beauties Re-awakened by Cytokine Kiss (Review). Immunol. Invest. 35 (2006) 1-18
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature. Rev. Cancer. 5 (2005) 263-274
5. Chiou S.H., Sheu B.C., Chang W.C., Huang S.C., and Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J. Reprod. Immunol. 67 (2005) 35-50
6. Uzzo R.G., Rayman P., Kolenko V., et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J. Clin. Invest. 104 (1999) 769-776
7. Broderick L., Brooks S.P., Takita H., Baer A.N., Bernstein J.M., and Bankert R.B. IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin. Immunol. 118 (2006) 159-169
8. Broderick L., and Bankert R.B. Membrane-associated TGF-β1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J. Immunol. 177 (2006) 3082-3088
9. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev., Immunol. 3 (2003) 133-146
10. Schmidt C.S., and Mescher M.F. Peptide antigen priming of naïve, but not memory, CD8 T cells require a third signal that can be provided by IL-12. J. Immunol. 168 (2002) 5521-5529
11. Kieper W.C., Prlic M., Schmidt C.S., Mescher M.F., and Jameson S.C. IL-12 enhances CD8 T cell homeostatic expansion. J. Immunol. 166 (2001) 5515-5521
12. Curtsinger J.M., Schmidt C.D., Mondino A., et al. Inflammatory cytokines provide a third signal for activation of naïve CD4+ and CD8+ cells. J. Immunol. 162 (1999) 3256-3262
13. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90 (1997) 2541-2548
14. Xu D., Gu P., Pan P.Y., Li Q., Sato A.I., and Chen S.H. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer. 109 (2004) 499-506
15. Kawamura T., Takeda K., Mendiratta S.K., et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J. Immunol. 160 (1998) 16-19
16. Estaquier J., Idziorek T., Zou W., et al. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J. Exp. Med. 182 (1995) 1759-1767
17. Brunda M.J. Interleukin-12. J. Leukoc. Biol. 55 (1994) 280-288
18. Noguchi Y., Richards E.C., Chen Y.T., and Old L.J. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2219-2223
19. Zou J.P., Yamamoto N., Fujii T., et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol. 7 (1995) 1135-1145
20. Brunda M.J., and Gately M.K. Interleukin-12: potential role in cancer therapy. Important Adv. Oncol. (1995) 3-18
21. Car B.D., Eng V.M., Lipman J.M., and Anderson T.D. The toxicology of interleukin-12: a review. Toxicol. Pathol. 27 (1999) 58-63
22. Cohen J. IL-12 deaths: explanation and a puzzle. Science 270 (1995) 908
23. Orange J.S., Salazar-Mather T.P., Opal S.M., et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181 (1995) 901-914
24. Atkins M.B., Robertson M.J., Gordon M., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3 (1997) 409-417
25. Dranoff G. The use of gene transfer in cancer immunotherapy. Forum (Genova) 8 (1998) 357-364
26. Colombo M.P., Vagliani M., Spreafico F., et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56 (1996) 2531-2534
27. Salem M.L., Gillanders W.E., Kadima A.N., et al. Novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J. Interferon Cytokine Res. 26 (2006) 593-608
28. Bankert R.B., Egilmez N.K., and Hess S.D. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22 (2001) 386-393
29. Hess S.D., Egilmez N.K., Bailey N., et al. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol. 170 (2003) 400-412
30. Broderick L., Yokota S.J., Reineke J., et al. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells. J. Immunol. 174 (2005) 898-906
31. Derrick T.S., Kashi R.S., Durrani M., Jhingan A., and Middaugh C.R. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J. Pharm. Sci. 93 (2004) 2549-2557
32. Stern A.S., Podlaski F.J., Hulmes J.D., et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. 87 (1990) 6808-6812
33. Lakowicz J.R. Principles of Fluorescence Spectroscopy. 2nd ed. (1999), Kluwer Academic/Plenum Publishers, New York
34. Nazareth M.R., Broderick L., Simpson-Abelson M.R., Kelleher Jr. R.J., Yokota S.J., and Bankert R.B. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol. 178 (2007) 5552-5562
35. null mice. J. Immunol. 180 (2008) 7009-7018
36. Oussoren C., Zuidema J., Crommelin D.J., and Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 1328 (1997) 261-272
37. Van Slooten M.L., Boerman O., Romoren K., Kedar E., Crommelin D.J., and Storm G. Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochim. Biophys. Acta 1530 (2001) 134-145
38. Allen T.M., Hansen C., and Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 981 (1989) 27-35
39. Ahl P.L., Chen L., Perkins W.R., et al. Interdigitation-fusion: a new method for producing lipid vesicles of high internal volume. Biochim. Biophys. Acta 1195 (1994) 237-244
40. Balasubramanian SV, Ramani K, Straubinger RM. Patent WO/2006/002195. Method of complexing a protein by the use of a dispersed system and proteins thereof.
41. Balasubramanian S.V., Bruenn J., and Straubinger R.M. Liposomes as formulation excipients for protein pharmaceuticals: a model protein study. Pharm. Res. 17 (2000) 344-350
42. Yoon C., Johnston S.C., Tang J., Stahl M., Tobin J.F., and Somers W.S. Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12. EMBO J. 19 (2000) 3530-3541
43. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
44. Appay V., Jandus C., Voelter V., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 177 (2006) 1670-1678
45. Rosenberg S.A., Sherry R.M., Morton K.E., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175 (2005) 6169-6176
46. Offringa R. Cancer. Cancer immunotherapy is more than a numbers game. Science 314 (2006) 68-69
47. Simpson-Abelson M., and Bankert R.B. Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. Expert Opin. Ther. Targets 12 (2008) 477-490
48. Zajac A.J., Blattman J.N., Murali-Krishna K., et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188 (1998) 2205-2213
49. Gallimore A., Glithero A., Godkin A., et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187 (1998) 1383-1393
50. Hill H.C., Conway Jr. T.F., Sabel M.S., et al. Cancer immunotherapy with interleukin-12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62 (2002) 7254-7263